Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06735924 · ClinicalTrials.gov registry record · NA

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

A NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT06735924 is a NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants, below the 109-participant average among 7 other MASLD trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06735924, a NA study of MASLD and Metabolic Dysfunction Associated Steatotic Liver Disease, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Interventions

  • DIETARY_SUPPLEMENT Low-oxalate fixed diet

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-04-26
Est. Completion 2027-12-31
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT06735924

The ClinicalTrials.gov registry entry for NCT06735924 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 7 other MASLD trials with a reported enrollment target (74% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with MASLD appearing as the primary indexed condition, and to 1 intervention - of which Low-oxalate fixed diet is the first listed.

NCT06735924 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT06735924 about?

NCT06735924 is a clinical study titled "Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis". This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

What is the current status of trial NCT06735924?

This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2023-04-26. Estimated completion is 2027-12-31.

What conditions does trial NCT06735924 study?

This clinical trial studies the following conditions: MASLD, Metabolic Dysfunction Associated Steatotic Liver Disease.

What interventions are being tested in trial NCT06735924?

The interventions under investigation include: Low-oxalate fixed diet (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06735924?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06735924 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for MASLD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.